Duke University Hospital

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Retrieved on: 
Tuesday, April 16, 2024
Duke University Hospital, American Heart Journal, American College, Congestion, Research, Baptist Memorial Hospital, Proxy, Heart failure, Pressure, Patient, BVA, Volume analysis, Letter, HF, Systemic, Medical imaging

Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.

Key Points: 
  • Data Presented at the American College of Cardiology Scientific Sessions;
    Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients.
  • Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA.
  • “These studies add to the numerous research papers and trials reporting the value of BVA at measuring congestion to improve outcomes,” stated Jonathan Feldschuh, Daxor’s Chief Scientific Officer.
  • A research letter published in the American Heart Journal, titled, ‘Prognostic Implications of Volume Status Assessed by Blood Volume Analysis in Ambulatory Heart Failure,’ was authored by leading heart failure experts from Duke University Medical Center, Baptist Memorial Hospital and Banner University Medical Center.

Reimagine Care Unveils Expansion of Distinguished Clinical Advisory Board to Advance Virtual-first Cancer Care Innovation

Retrieved on: 
Tuesday, April 30, 2024
General Health, Health, Health Technology, Telemedicine, Virtual Medicine, Oncology, ION, EHR, Doctor of Philosophy, ASCO, Legislation, Medicine, Medical director, MHS, Knowledge, NCCS, Nursing, MPP, Informatics, Publication, Advisory board, Research, Public policy, Multimedia, Clinical trial, CTCA, Duke University Hospital, University, Cancer, Policy, EMR, Business development, MD, Duke, Patient, Doctor of Pharmacy, Society, Caregiver, Duke Cancer Institute

Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical Advisory Board with the appointment of renowned healthcare professionals with expertise in care across the cancer continuum.

Key Points: 
  • Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical Advisory Board with the appointment of renowned healthcare professionals with expertise in care across the cancer continuum.
  • Comprised of distinguished leaders, the board is poised to provide strategic guidance and insight to further enhance Reimagine Care's innovative solutions.
  • View the full release here: https://www.businesswire.com/news/home/20240430740623/en/
    Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical Advisory Board with the appointment of renowned healthcare professionals with expertise in care across the cancer continuum.
  • "We are delighted to welcome such a talented and acclaimed group of professionals to our Clinical Advisory Board," said Dan Nardi, CEO of Reimagine Care.

Cross Country EVP, Chief Administrative Officer and General Counsel Named to Global Top 50 Corporate Counsel List

Retrieved on: 
Wednesday, April 24, 2024
Professional Services, Health, Practice Management, Other Health, Human Resources, General Health, Consulting, Corporation, Florida Atlantic University, Duke University Hospital, Master of Business Administration, New York Law School, General counsel, EVP, Business administration, Ohio State University, Corporate lawyer, Nursing, Cross country, Atlantic University, Trust, Multimedia, Ethics, Growth, Woman

Cross Country Healthcare, a market-leading, tech-enabled workforce solutions platform and advisory firm, is proud to announce that Susan E. Ball, EVP, Chief Administrative Officer, General Counsel and Corporate Secretary, has been recognized on the 2024 OnCon Icon Awards list as one of the top 50 corporate counsels in the world.

Key Points: 
  • Cross Country Healthcare, a market-leading, tech-enabled workforce solutions platform and advisory firm, is proud to announce that Susan E. Ball, EVP, Chief Administrative Officer, General Counsel and Corporate Secretary, has been recognized on the 2024 OnCon Icon Awards list as one of the top 50 corporate counsels in the world.
  • View the full release here: https://www.businesswire.com/news/home/20240424054273/en/
    Cross Country EVP, Chief Administrative Officer and General Counsel, Susan E. Ball, Named to Global Top 50 Corporate Counsel List.
  • (Photo: Business Wire)
    "I'm deeply honored to be included in the 2024 OnCon Icon Top 50 Corporate Counsel list.
  • This recognition is a testament to the support I have received from Cross Country Healthcare’s Board of Directors and management teams over the years to drive excellence in all that we do,” said Susan E. Ball, EVP, Chief Administrative Officer, General Counsel and Corporate Secretary of Cross Country.

Renowned Alzheimer's Neurologist Dale Bredesen, MD, Joins Pacific Neuroscience Institute

Retrieved on: 
Tuesday, April 16, 2024
UCLA, Neurodegenerative disease, Alzheimer's disease, Duke University Hospital, Brain, University, Dementia, Recode, Hope, NIH, Risk, Arrest, University of California, PNI, Doctor of Philosophy, The New York Times, Research, Trial of the century, History, Confusion, Exercise, Documentation, Ageing, UCSF, Buck, Patient, Survivor, Neurology, Medicine, Faculty, Amnesia, Quality of life, Nobel, UC, Nursing

SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®. Over the past four months, as the senior director of the nascent Precision Brain Health program, he and his colleagues have been intensely focused on developing what promises to be the world's first formalized system to comprehensively address neurodegenerative disease in the world. While not quite ready for primetime, the excitement around the clinical implications for patients is palpable.

Key Points: 
  • SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.
  • Taking a personalized, biological systemwide approach and becoming proactive about interventions, represent the first steps towards stopping Alzheimer's in its tracks."
  • Pacific Neuroscience Institute has a history of innovation that fits perfectly with the development of this novel program."
  • He directed the Program on Aging at the Burnham Institute and joined the Buck Institute as founding president and CEO.

Burn Boot Camp and Muscular Dystrophy Association Team Up for 8th Annual 'Be Their Muscle' Philanthropic Event

Retrieved on: 
Monday, March 25, 2024
Research, Employment, Entrepreneurship, Skeletal muscle, MDA, ALS, Partnership, Air travel, Education, Duke University Hospital, Social media, Muscular dystrophy, Muscular Dystrophy Association, Senior, Empowerment, Duchenne muscular dystrophy, Duchenne, Clinical trial, FDA, Summer camp, Pharmaceutical industry

Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.

Key Points: 
  • Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.
  • Muscular Dystrophy Association is one of Burn Boot Camp's longest-standing national philanthropic partners," explained Morgan Kline, CEO and Co-Founder of Burn Boot Camp.
  • "Here at the Muscular Dystrophy Association, we stand hand in hand with Burn Boot Camp in our shared commitment to empower communities nationwide.
  • MDA and Burn Boot Camp will be posting throughout the campaign on social media using @MDAorg and @burnbootcamp with #BeTheirMuscle.

Paragonix Technologies Announces Nationwide Commercial Availability of FDA-Cleared BAROguard™ Donor Lung Preservation System

Retrieved on: 
Thursday, April 4, 2024
FDA, Health Technology, Health, Medical Devices, Lung, Massachusetts General Hospital, International Society, Transplant, Patient, Duke University Hospital, Research, Standard of care, Lung transplantation, MD, Surgeon, MSC, UCSF Medical Center, Atmosphere, Hospital, UCLA, Heart, UCLA Health, Medical device

Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .

Key Points: 
  • Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .
  • First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection.
  • Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023.
  • “The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

Retrieved on: 
Friday, March 8, 2024
BVA, Anemia, Blood, Kidney, Duke University Hospital, Risk, Conference, Heart failure, Prevalence, Patient, Kidney disease, Diagnosis, Correlation, THT, Pressure, Medical imaging

Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

Key Points: 
  • Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
  • The study, titled, ‘Blood Volume Profiles and Correlations with Pressures in Heart Failure with Impaired Renal Function,’ aimed to answer if the degree of renal impairment in heart failure patients impacts volume status, the pressure-volume relationship, and the prevalence and types of anemia.
  • Veraprapas Kittipibul M.D., lead investigator of the study concluded that:
    Heterogeneity in volume exists across renal function which can only be accurately measured with BVA.
  • Patients with large volume expansion had worsening renal function, showing the urgent need for care.

FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Surgery, Health Technology, Clinical Trials, Cardiology, Division, Hypervolemia, Surgeon, Rochester General Hospital, Ohio State University, Weill Cornell Medicine, Hospital, Duke University Hospital, Inferior vena cava, Heart failure, Patient, Medicine, IVC, Ageing, Physician, Pressure, Medical imaging

Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Key Points: 
  • Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.
  • The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.
  • FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care.
  • “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley.

Heart Failure Monitoring Technology Doubles Sensitivity for Predicting Events While Minimizing False Alerts Versus Standard of Care

Retrieved on: 
Wednesday, March 6, 2024
SAN, Algorithm, Peter Hancock (professor), MD, FDA, MHS, Hospital, Standard of care, Duke University Hospital, Heart failure, Biomarker, Patient, THT, Observational study, Research, Pharmaceutical industry

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

Key Points: 
  • SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
  • It demonstrated this using the same monitoring routine patients already follow in weighing themselves daily and concurrently minimized false alerts for care teams, generating nearly 40 percent fewer overall alerts.
  • Over the course of the study, the Congestion Index correctly predicted 48 of 69 heart failure events (70%), demonstrating significantly higher sensitivity (p
  • In addition to demonstrating greater sensitivity in detecting heart failure events, the Congestion Index did so with a lower alert rate, generating only 2.58 alerts per patient-year compared to the 4.18 produced by the standard of care.